Handelsavisen
prelaunch
Companies Healthcare 4564.T
45
4564.T Tokyo Stock Exchange Biotechnology & Medical Research

4564.T

¥20,00
Open in Charts → Attach watcher ⌖
JPY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
8,0B JPY
P/E
EV / Rev
Div yield
0,00 %
Op margin
-106,1 %
ROE
-111,8 %
Net margin
-108,7 %
Debt / equity
0,07
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotechnology products.

Business. The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotechnology products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-111,8 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 4564.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 4564.T. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotechnology products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    The company maintains a strong liquidity position, with cash and equivalents amounting to 833,883,000 JPY, significantly exceeding its total liabilities of 426,092,000 JPY, as reflected in a current ratio of 3.37. The price-to-book ratio of 11.48 indicates that the market is valuing the company's equity at a premium relative to its book value. However, the company's operating cash flow is negative at -815,021,000 JPY, suggesting that it is not generating sufficient cash from operations to sustain its activities.

    Profitability metrics are concerning, with a net loss of 815,285,000 JPY and a return on equity of -1.1182, indicating that the company is not generating returns for its shareholders. The return on assets of -0.7058 further underscores the inefficiency in asset utilization to generate profits. The company's gross profit is also negative at -12,756,000 JPY, highlighting the challenges in managing production and operational costs.

    The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration may expose the company to higher risks if the segment or region experiences a downturn. The company's operating income is negative at -796,015,000 JPY, indicating that it is not profitable from its core operations.

    The company's growth trajectory is uncertain, with a net loss in the most recent fiscal year and no clear indication of improvement in the near term. The operating income and net income are both negative, suggesting that the company is not on a path to profitability. The company's capital expenditure is relatively low at -279,000 JPY, indicating minimal investment in long-term assets.

    The company's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The debt-to-equity ratio of 0.07 suggests that the company is not heavily leveraged, reducing its financial risk. The company's capital structure is primarily equity-based, with total equity of 729,111,000 JPY and long-term debt of 51,067,000 JPY.

    Recent events, as disclosed in the company's financial filings, do not indicate any significant changes in its business operations or financial position. The company's market price is 21.0 JPY, and its market capitalization is 8,371,515,012 JPY, reflecting the market's perception of its value. The company's shares outstanding are 398,643,572, with no difference between basic and diluted shares, indicating no significant dilution risk.

    Key takeaways
    • The company has a strong liquidity position with a current ratio of 3.37 and significant cash reserves.
    • The company is not profitable, with a net loss of 815,285,000 JPY and negative returns on equity and assets.
    • The company's revenue is concentrated in a single business segment, increasing its exposure to market risks.
    • The company's growth trajectory is uncertain, with no clear path to profitability in the near term.
    • The company has low liquidity and dilution risks, with a debt-to-equity ratio of 0.07.
    • **margin_outlook_rationale**: The company's gross profit is negative, indicating that it is not able to cover its production costs, which is a significant concern for its margin outlook.
    • **rd_outlook_rationale**: The company's financial statements do not provide specific information on research and development expenditures, making it difficult to assess the outlook for R&D.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥20,00
    Market cap
    ¥8.37B
    Enterprise value
    ¥7.59B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    11.5x
    P / Tangible book
    11.5x
    Tangible book
    ¥729.1M
    Net cash
    ¥782.8M
    Current ratio
    3.4
    Debt / equity
    0.1
    ROA
    -70.6%
    ROE
    -1.1%
    Cash conversion
    100.0%
    CapEx / revenue
    -0.0%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-106,1 %Above median
    Net Margin-108,7 %Above median
    ROE-111,8 %Bottom quartile
    Capex / Rev-0,0 %Above P75
    D/E0,07Below median
    Cash Conv1,00Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • 4564.T Market data — financials · 2026-05-26
    • OncoTherapy Science Inc Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    4564.TCanonical
    Tokyo Stock Exchange · JPY

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage